Table 4.

Multiple Linear Regression Analysis

	PGE2		COX2		NO- 2		TBARS		15d-PGJ2		PPARγ act.
	ß	P	ß	P	ß	P	ß	P	ß	P	ß	P
Gender (ref. female)	−45.635	.805	−37.395	.426	7.451	.015	1.793	.083	−31.095	.625	−0.179	.632
Age	−5.010	.759	−0.462	.915	−0.042	.870	0.108	.232	−11.284	.052	0.075	.048
Body mass index	−1.898	.932	5.596	.281	−0.038	.903	−0.217	.073	2.463	.743	−0.141	.093
Antipsychotic DDD	−0.733	.028	0.148	.085	0.006	.236	−0.001	.604	0.333	.006	0.000	.888
DUP	1.020	.462	0.187	.578	0.019	.355	−0.013	.080	−0.025	.957	0.003	.274
GAF	−3.401	.660	2.490	.206	0.122	.263	−0.120	.005	0.783	.763	−0.033	.024
Cannabis use per month	−0.619	.890	−1.296	.215	−0.190	.008	0.015	.531	0.994	.510	−0.003	.714
Cotinine plasma levels	−3.387	.007	0.672	.046	0.001	.955	0.001	.927	0.503	.225	0.002	.343
DUBM	0.714	.017	−0.047	.500	0.001	.837	0.005	.002	−0.057	.563	0.000	.555

Abbreviations: ß, linear regression coefficient; BMI, body mass index; DDD, defined daily dose of antipsychotic chlorpromazine equivalents; DUBM, number of days elapsed between the onset of the FEP and blood samplings; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale.

Change of each biological marker (from baseline to the follow-up point) depending on demographic and clinical variables. The bold values in the table represents the values reaching statistical significance (P<.05).